Centre Approves Biological E Study For Its COVID-19 Vaccine In Children, Teens

Amid the ongoing vaccination drive for the 18 years old above, the Central Government announced, on Friday, that the Drugs Controller General of India (DCGI) has approved the Biological E for two clinical trials of its Coronavirus vaccine candidate Corbevax. 

Now with the DCGI approval, domestic vaccine makers can start studies for its COVID-19 vaccine in children and teenagers. 

DCGI, the Indian regulator, gave the green signal to the Hyderabad-based pharmaceutical company on 1 September. Hence, now this company can study the safety and tolerability of its vaccine, CORBEVAX, in this population, its official statement. 

Currently, a total of 6 vaccines have been authorized for use in India. Talking about the vaccination, according to Johns Hopkins data, a total of 11.28 per cent of the entire population has been fully vaccinated so far. Two major vaccines in India are Covaxin and Covishield manufactured by Bharat Biotech and Serum Institute of India. 

Meanwhile, the Indian government in August already approved Cadila's Coronavirus vaccine which is the world's first DNA dose against the deadly virus, for emergency use in 12 years children and above.

Talking about Biological E, it is also running a late-stage trial of its vaccine in adults.